Patient characteristics
| Demographics . | Total cohort (N = 162) . | BCA (n = 114) . | No BCA (n = 48) . | P value . |
|---|---|---|---|---|
| Median age (range) | 15.8 (4.3-38.7) | 16.9 (4.3-38.7) | 14.9 (4.8-34.6) | .70 |
| Sex | ||||
| Male | 112 (69.1%) | 78 (68.4%) | 34 (70.8%) | .85 |
| Female | 50 (30.9%) | 36 (31.6%) | 14 (29.2%) | |
| Prior therapy | ||||
| Median number of prior treatments (range) | 4 (1-14) | 4.5 (1-13) | 4 (2-14) | .56 |
| Prior transplant (HSCT) | 89 (54.9%) | 53 (46.5%) | 36 (75.0%) | .001 |
| Median time from prior HSCT∗ (range), mo | 22.2 (3.8-178.1) | 20.9 (3.8-178.1) | 24.0 (7.3-174.3) | .99 |
| Prior CAR T cells | 64 (39.5%) | 48 (42.1%) | 16 (33.3%) | .38 |
| Prior blinatumomab | 56 (34.6%) | 38 (33.3%) | 18 (37.5%) | .72 |
| Prior inotuzumab | 30 (18.5%) | 20 (17.5%) | 10 (20.8%) | .66 |
| Any prior immunotherapy (including CAR T cells, blinatumomab, or inotuzumab) | 102 (63.0%) | 70 (61.4%) | 32 (66.7%) | .53 |
| Marrow disease burden before LD chemotherapy | ||||
| M1 marrow | 56 (34.6%) | 34 (29.8%) | 22 (45.8%) | .07 |
| M2 or greater | 106 (65.4%) | 80 (70.2%) | 26 (54.2%) | |
| Most proximal prior therapy | ||||
| None | 49 (30.2%) | 28 (24.6%) | 21 (43.8%) | N/A |
| Maintenance | 80 (49.4%) | 59 (51.8%) | 21 (43.8%) | |
| Intensive chemotherapy | 28 (17.3%) | 22 (19.3%) | 6 (12.5%) | |
| Immunotherapy | 1 (0.6%) | 1 (0.9%) | 0 (0.0%) | |
| Other | 4 (2.5%) | 4 (3.5%) | 0 (0.0%) |
| Demographics . | Total cohort (N = 162) . | BCA (n = 114) . | No BCA (n = 48) . | P value . |
|---|---|---|---|---|
| Median age (range) | 15.8 (4.3-38.7) | 16.9 (4.3-38.7) | 14.9 (4.8-34.6) | .70 |
| Sex | ||||
| Male | 112 (69.1%) | 78 (68.4%) | 34 (70.8%) | .85 |
| Female | 50 (30.9%) | 36 (31.6%) | 14 (29.2%) | |
| Prior therapy | ||||
| Median number of prior treatments (range) | 4 (1-14) | 4.5 (1-13) | 4 (2-14) | .56 |
| Prior transplant (HSCT) | 89 (54.9%) | 53 (46.5%) | 36 (75.0%) | .001 |
| Median time from prior HSCT∗ (range), mo | 22.2 (3.8-178.1) | 20.9 (3.8-178.1) | 24.0 (7.3-174.3) | .99 |
| Prior CAR T cells | 64 (39.5%) | 48 (42.1%) | 16 (33.3%) | .38 |
| Prior blinatumomab | 56 (34.6%) | 38 (33.3%) | 18 (37.5%) | .72 |
| Prior inotuzumab | 30 (18.5%) | 20 (17.5%) | 10 (20.8%) | .66 |
| Any prior immunotherapy (including CAR T cells, blinatumomab, or inotuzumab) | 102 (63.0%) | 70 (61.4%) | 32 (66.7%) | .53 |
| Marrow disease burden before LD chemotherapy | ||||
| M1 marrow | 56 (34.6%) | 34 (29.8%) | 22 (45.8%) | .07 |
| M2 or greater | 106 (65.4%) | 80 (70.2%) | 26 (54.2%) | |
| Most proximal prior therapy | ||||
| None | 49 (30.2%) | 28 (24.6%) | 21 (43.8%) | N/A |
| Maintenance | 80 (49.4%) | 59 (51.8%) | 21 (43.8%) | |
| Intensive chemotherapy | 28 (17.3%) | 22 (19.3%) | 6 (12.5%) | |
| Immunotherapy | 1 (0.6%) | 1 (0.9%) | 0 (0.0%) | |
| Other | 4 (2.5%) | 4 (3.5%) | 0 (0.0%) |
BCA as defined by BCA <50 cells per μL. High disease burden defined as ≥M2 marrow and low disease burden defined as <M2 marrow.
N/A, not applicable.
Date of prior HSCT available on 85 (of 89) patients: 51 of 53 patients with BCA and 34 of 36 patients without BCA.